Sorafenib in The Treatment of Advanced Hepatocellular Carcinoma  

Oleh:

Mousa, Ali Ben

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Saudi Journal of Gastroenterology vol. 14 no. 01 (Jan. 2008), page 40.
Topik: Hepatocellular carsinoma; kinase inhibitir; sorafenib

Ketersediaan

Perpustakaan FK Nomor Panggil: T02.K.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Management of advanced Hepatocellular carsinoma (HCC) is still a challenge to physicians since these patients are not candidates for surgical or ablative therapy. The disease carries a very poor prognosis with an expected survival of 4-6 moths. No chemotherapeutic agents has been proven to improve the clinical outcomes in such patients. A multikinase inhibitor, sorafenib, previously tested and found effective in other solid tumors recently found to significantly improve survival in patient with advanced HCC. Sorafenib exerts its action through inhibition of several kinase involvved in both tumour cell poliferation and angiogenesis. it was well tolerated at a dose of 400 mg twice daily and permanent discontinuation of the drug was rarely required.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali